Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Equity Average (2016 - 2025)

Historic Equity Average for Corcept Therapeutics (CORT) over the last 11 years, with Q3 2025 value amounting to $633.8 million.

  • Corcept Therapeutics' Equity Average rose 264.09% to $633.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.8 million, marking a year-over-year increase of 264.09%. This contributed to the annual value of $593.1 million for FY2024, which is 1762.41% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Equity Average stood at $633.8 million, which was up 264.09% from $659.5 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Equity Average high stood at $681.4 million for Q1 2025, and its period low was $391.8 million during Q1 2022.
  • Moreover, its 5-year median value for Equity Average was $516.7 million (2021), whereas its average is $529.1 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 2422.52% in 2022, then soared by 3982.65% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Equity Average (Quarter) stood at $458.0 million in 2021, then grew by 6.46% to $487.6 million in 2022, then fell by 0.7% to $484.2 million in 2023, then soared by 36.15% to $659.2 million in 2024, then dropped by 3.85% to $633.8 million in 2025.
  • Its last three reported values are $633.8 million in Q3 2025, $659.5 million for Q2 2025, and $681.4 million during Q1 2025.